The system is designed to simplify endovascular procedures and to treat patients with abdominal aortic aneurysms.

The company said it is currently implementing a few enhancements to the Nellix system intended to further optimize the device for commercialization.

The company will submit the enhancements to its Notified Body, in order to gain CE mark approval in Europe by the end of the second quarter 2013.

Endologix president and chief executive officer John McDermott said the company has the potential to treat more AAA patients and get better clinical outcomes than any other device for the endovascular repair of AAA.

"Receiving CE Mark for the current version of the system is an important regulatory milestone and we look forward to providing this ground-breaking technology to physicians and their patients in 2013," McDermott added.